Comparison of two corticosteroid regimens on brain volumetrics in patients with Duchenne muscular dystrophy
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objective: Duchenne muscular dystrophy (DMD) is a neuromuscular disorder in which many patients also have neurobehavioral problems. Corticosteroids, the primary pharmacological treatment for DMD, have been shown to affect brain morphology in other conditions, but data in DMD are lacking. This study aimed to investigate the impact of two corticosteroid regimens on brain volumetrics in DMD using magnetic resonance imaging (MRI). Methods: In a cross‐sectional, two‐center study, T1‐weighted MRI scans were obtained from three age‐matched groups (9–18 years): DMD patients treated daily with deflazacort (DMDd, n = 20, scan site: Leuven), DMD patients treated intermittently with prednisone (DMDi, n = 20, scan site: Leiden), and healthy controls (n = 40, both scan sites). FSL was used to perform voxel‐based morphometry analyses and to calculate intracranial, total brain, gray matter, white matter, and cerebrospinal fluid volumes. A MANCOVA was employed to compare global volumetrics between groups, with site as covariate. Results: Both patient groups displayed regional differences in gray matter volumes compared to the control group. The DMDd group showed a wider extent of brain regions affected and a greater difference overall. This was substantiated by the global volume quantification: the DMDd group, but not the DMDi group, showed significant differences in gray matter, white matter, and cerebrospinal fluid volumes compared to the control group, after correction for intracranial volume. Interpretation: Volumetric differences in the brain are considered part of the DMD phenotype. This study suggests an additional impact of corticosteroid treatment showing a contrast between pronounced alterations seen in patients receiving daily corticosteroid treatment and more subtle differences in those treated intermittently.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies on chronic corticosteroid use have revealed correlations between corticosteroid dose and regimen and the extent of alterations in brain volume and white matter microstructure (Van Der Meulen et al., 2022; Geuens et al., 2023).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Geuens et al., 2023
In the citing paper
“Chronic corticosteroid treatment exacerbates grey matter volume reductions (Geuens et al., 2023), white matter alterations (Van Der Meulen et al., 2022) and behavioural problems in individuals with DMD (Angelini, 2007; Counterman et al., 2022).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Geuens et al., 2023
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brain charts for the human lifespan
Bethlehem, R. A. I., Seidlitz, J., White, S. R., Vogel, J. W., Anderson, K. M., Adamson, C., Adler, S., Alexopoulos, G. S., Anagnostou, E., Areces-Gonzalez, A., et al. (2022) · Nature · doi:10.1038/s41586-022-04554-y · Cited by 1,794 · cited 1×
“56 Finally, our study design and sample size did not allow to investigate relations between brain parameters and other variables such as mutation site, cognitive abilities, and behavioral outcomes.”
BackgroundCorticosteroids for the treatment of Duchenne muscular dystrophy
Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., & Manzur, A. Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub4 · Cited by 493
Grossmann, C., Scholz, T., Rochel, M., Bumke-Vogt, C., Oelkers, W., Pfeiffer, A., Diederich, S., & Bahr, V (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510397 · Cited by 212 · cited 1×
“52 In addition, daily corticosteroid treatment is expected to chronically suppress cortisol levels, which leads to a chronic inhibition of cortisol-induced natural hormonal processes.”
BackgroundExogenous glucocorticoids and adverse cerebral effects in children
Damsted, S. K., Born, A. P., Paulson, O. B., & Uldall, P. (2011) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2011.05.002 · Cited by 51 · cited 2×
“29,30,47,48 25 – 28 However, it is important to note that the treatment duration for these conditions typically ranges from weeks to months, whereas individuals with DMD receive corticosteroid treatment starting from an early age (4 – 5 years) continuing into adulthood, resulting in a much longer…”
Background
Research works printed but not linked: 51
- 10.3233/JND-140045 · DOI · Paper page
- 10.1016/S1474-4422(18)30024-3 · DOI · Paper page
- 10.3390/genes11080837 · DOI · Paper page
- 10.1001/jama.2022.4315 · DOI · Paper page
- 10.1038/s41598-017-12981-5 · DOI · Paper page
- 10.1002/mus.26803 · DOI · Paper page
- 10.1111/dmcn.12922 · DOI · Paper page
- 10.1016/j.jpeds.2012.03.020 · DOI · Paper page
- 10.1212/WNL.0000000000008363 · DOI
- 10.3390/brainsci12111544 · DOI
- 10.1002/ana.24222 · DOI · Paper page
- 10.1016/j.nmd.2020.05.001 · DOI
- 10.3174/ajnr.A6604 · DOI · Paper page
- 10.1007/s00415-021-10789-y · DOI · Paper page
- 10.1002/mus.10238 · DOI · Paper page
- 10.1002/nbm.1582 · DOI · Paper page
- 10.1016/j.nmd.2016.10.005 · DOI
- 10.1016/j.nmd.2022.02.008 · DOI
- 10.1016/j.nmd.2020.08.357 · doi:10.1016/j.nmd.2020.08.357
- 10.1016/j.brainres.2009.03.036 · DOI
- De Kloet ER, 1998, Brain corticosteroid receptor balance in health and disease, Endocr Rev, 19, 269
- 10.1159/000101917 · DOI · Paper page
- 10.3389/fnins.2021.604103 · DOI · Paper page
- 10.1016/j.nicl.2019.101825 · DOI
- 10.1038/pr.2017.312 · DOI
- 10.1111/apa.13010 · DOI
- Meulen M, 2022, Association between use of systemic and inhaled glucocorticoids and changes in brain volume and white matter microstructure: a cross‐sectional study using data from the UK biobank, BMJ Open, 12, 10.1136/bmjopen-2022-062446 · DOI · Paper page
- 10.1016/j.biopsych.2003.09.010 · DOI · Paper page
- 10.1016/S0893-133X(99)00054-8 · DOI · Paper page
- 10.1016/j.biopsych.2007.09.014 · DOI
- 10.1097/JCP.0000000000001120 · DOI
- 10.1176/appi.ajp.2014.13091264 · DOI · Paper page
- 10.1080/15622975.2019.1585946 · DOI
- 10.1016/j.neuroimage.2011.09.015 · DOI · Paper page
- 10.1016/j.neuroimage.2004.07.051 · DOI · Paper page
- 10.1016/j.neuroimage.2008.10.055 · DOI · Paper page
- 10.1006/nimg.2002.1132 · DOI · Paper page
- 10.1016/S1361-8415(01)00036-6 · DOI · Paper page
- 10.1002/hbm.10062 · DOI · Paper page
- 10.1109/42.906424 · DOI · Paper page
- 10.1093/brain/awm184 · DOI · Paper page
- 10.1006/nimg.2001.0786 · DOI · Paper page
- IBM Corp, 2021, IBM SPSS Statistics
- 10.1038/s41398-020-00980-6 · DOI
- 10.1097/MED.0000000000000414 · DOI
- 10.1016/j.neuroscience.2019.05.050 · DOI
- 10.1212/WNL.0000000000002337 · DOI · Paper page
- 10.1016/j.pmr.2012.08.003 · DOI
- 10.1212/WNL.0000000000001950 · DOI · Paper page
- 10.1155/2015/450341 · DOI · Paper page
- 10.1002/jmri.22576 · DOI
Cited by
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Self-citation
Metadata
- Authors
- Geuens, S., Van Dessel, J., Govaarts, R., Ikelaar, N. A., Meijer, O. C., Kan, H. E., Niks, E. H., Goemans, N., Lemiere, J., Doorenweerd, N., & De Waele, L.
- Affiliations
- Child Neurology University Hospitals Leuven Leuven Belgium
- Department of Neurosciences, Center for Developmental Psychiatry UPC‐KU Leuven Leuven Belgium
- C.J. Gorter MRI Center, Radiology Leiden University Medical Center Leiden Netherlands
- Duchenne Center Netherlands Leiden Netherlands
- Department of Medicine Leiden University Medical Center Leiden Netherlands
- Pediatric Hemato‐Oncology University Hospitals Leuven Leuven Belgium
- ORCID
- Geuens, Sam
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2023-10-12
- Volume
- 10
- Issue
- 12
- Pages
- 2324-2333
- ISSN
- 2328-9503
- Cited by
- 11
- References
- 4
- Language
- en
- Funders
- Rondoufonds voor Duchenneonderzoek
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.